The MarketReader Minute
π CRISPR Therapeutics Gains Following FDA Designation, AbbVie and Regeneron Show Positive Trends | Biotech Sector Insights
(IBB) has seen a price increase since Friday. The Reserve Bank of Australia has cut its cash rate by 25 basis points to 4.10%, the first reduction in four years, which may stimulate economic activity and investment in the biotech sector.